{"protocolSection":{"identificationModule":{"nctId":"NCT06482437","orgStudyIdInfo":{"id":"NMD670-02-0003"},"organization":{"fullName":"NMD Pharma A/S","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease","officialTitle":"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 Over 21 Days in Ambulatory Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease","acronym":"SYNAPSE-CMT"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-25","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-03-16","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03-16","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"NMD Pharma A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type."},"conditionsModule":{"conditions":["Charcot-Marie-Tooth Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":80,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NMD670","type":"EXPERIMENTAL","interventionNames":["Drug: NMD670"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"NMD670","description":"Tablets taken twice daily for 21 days","armGroupLabels":["NMD670"]},{"type":"DRUG","name":"Placebo","description":"Tablets taken twice daily for 21 days","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change from baseline to day 21 in 6-minute walk test total distance for NMD670 vs placebo","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in the time to complete 10 meter walk/run test for NMD670 vs placebo","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in the time to complete timed-up-and-go for NMD670 vs placebo","timeFrame":"Baseline to day 21"}],"secondaryOutcomes":[{"measure":"Change from baseline to day 21 in CMT Functional Outcome Measure Total Score and Individual Items for NMD670 vs placebo","description":"CMT Functional Outcome Meausre is a 12-item scale. Scale goes from 0-100 and a higher score indicates worse symptomatology","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in 6-minute walk test fatigue index for NMD670 vs placebo","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in Overall Neuropathy Limitation Scale total score and individual items for NMD670 vs placebo","description":"The Overall Neuropathy Limitation Scale consists of an arm and a leg scale. Scale goes from 0-12 and a higher score indicates worse symptomatology","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in CMT Health Index total score and individual domains for NMD670 vs placebo","description":"The CMT Health Index has 18 domains. Scale goes from 0-100 and a higher score indicates worse symptomatology","timeFrame":"Baseline to day 21"},{"measure":"Change from baseline to day 21 in SF-36 total score and individual domains for NMD670 vs placebo","description":"The SF-36 has 8 domains. Scale goes from 0-100 and a lower score indicates worse symptomatology","timeFrame":"Baseline to day 21"},{"measure":"Incidence of treatment emergent adverse events","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of serious treatment emergent adverse events","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of clinically significant abnormalities on physical examinations","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of clinically significant abnormalities on safety laboratory parameters","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of clinically significant vital signs abnormalities","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of clinically significant ECG abnormalities","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of Suicidal Ideation or Suicidal Behavior","description":"Summarised per treatment","timeFrame":"Over 21 days of dosing"},{"measure":"Incidence of clinically significant abnormalities on opthalmological examinations","description":"Summarised per treatment","timeFrame":"From screening (day -28 to day -1) until follow up (day 28)]"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female participants must be 18 to 70 years inclusive at the time of signing the ICF.\n* Diagnosis of CMT type 1 or 2 confirmed by genetic testing.\n* Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg\n* Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n* Participant is capable of and has given signed informed consent\n\nExclusion Criteria:\n\n* Participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular diseases) and/or ability to complete the tests, in the opinion of the Investigator.\n* Participants with laboratory test result abnormalities at screening considered clinically significant by the Investigator.\n* Participants who have received treatment with another IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1.\n* Participants with history of poor compliance with relevant therapy in the opinion of the Investigator.\n* Female participants who plan to become pregnant during the study or are currently pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"contact@nmdpharma.com","role":"CONTACT","phone":"contact@nmdpharma.com","email":"contact@nmdpharma.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000014076","term":"Tooth Diseases"},{"id":"D000002607","term":"Charcot-Marie-Tooth Disease"},{"id":"D000009408","term":"Nerve Compression Syndromes"},{"id":"D000015417","term":"Hereditary Sensory and Motor Neuropathy"}],"ancestors":[{"id":"D000009057","term":"Stomatognathic Diseases"},{"id":"D000009421","term":"Nervous System Malformations"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000020271","term":"Heredodegenerative Disorders, Nervous System"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000011115","term":"Polyneuropathies"},{"id":"D000010523","term":"Peripheral Nervous System Diseases"},{"id":"D000009468","term":"Neuromuscular Diseases"},{"id":"D000000013","term":"Congenital Abnormalities"},{"id":"D000030342","term":"Genetic Diseases, Inborn"}],"browseLeaves":[{"id":"M16831","name":"Tooth Diseases","asFound":"Tooth Disease","relevance":"HIGH"},{"id":"M5853","name":"Charcot-Marie-Tooth Disease","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"M12352","name":"Nerve Compression Syndromes","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"M18092","name":"Hereditary Sensory and Motor Neuropathy","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"M16355","name":"Syndrome","relevance":"LOW"},{"id":"M12017","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"M12","name":"Congenital Abnormalities","relevance":"LOW"},{"id":"M12365","name":"Nervous System Malformations","relevance":"LOW"},{"id":"M22092","name":"Heredodegenerative Disorders, Nervous System","relevance":"LOW"},{"id":"M21558","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M13999","name":"Polyneuropathies","relevance":"LOW"},{"id":"M13432","name":"Peripheral Nervous System Diseases","relevance":"LOW"},{"id":"M12411","name":"Neuromuscular Diseases","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"T1081","name":"Charcot-Marie-Tooth Disease","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"T2761","name":"Hereditary Motor and Sensory Neuropathy","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"T2766","name":"Hereditary Neuropathy With Liability to Pressure Palsies","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"},{"id":"T5067","name":"Roussy Levy Syndrome","asFound":"Charcot-Marie-Tooth Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}